贝达喹啉、德拉马尼与利奈唑胺联合方案在小鼠结核模型中疗效优于标准方案
该研究在小鼠结核模型中比较了全口服耐药结核方案贝达喹啉(25 mg/kg)、德拉马尼(2.5 mg/kg)和利奈唑胺(100 mg/kg)(BDL)与标准方案异烟肼、利福平、吡嗪酰胺和乙胺丁醇(HRZE)的疗效。BDL组肺培养转阴时间为8周,HRZE组为20周;停药后12周评估复发,BDL组仅1只小鼠复发,而HRZE组至24周仍有复发。数学模型预测BDL和HRZE达到95%治愈率分别需20.5周和28.5周。
要点
- BDL方案肺培养转阴时间(8周)早于HRZE(20周)。
- BDL组停药后复发极少,HRZE组至24周仍有复发。
- 模型预测BDL达到95%治愈率所需疗程短于HRZE。
核心结论
- BDL方案在小鼠结核模型中疗效优于HRZE,可能为耐药结核治疗的有价值选择。
研究设计与样本
- 研究比较BDL(贝达喹啉25 mg/kg、德拉马尼2.5 mg/kg、利奈唑胺100 mg/kg)与HRZE方案在结核感染小鼠中治疗24周的疗效。
- 治疗结束后12周评估复发,并建立两个逻辑回归模型比较两种方案的疗效。
主要发现
- BDL组和HRZE组肺培养转阴分别在第8周和第20周实现。
- 治疗14周后BDL组仅1只小鼠复发,而HRZE组至24周仍有复发。
- 最终数学模型预测BDL和HRZE达到95%治愈率分别需20.5周和28.5周。
临床怎么用
- BDL全口服联合方案可能缩短耐药结核疗程并降低复发,但需临床研究验证。
局限性
- 研究为小鼠模型,结果不能直接外推至人类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The treatment success rate of drug-resistant (DR) tuberculosis is alarmingly low. Therefore, more effective and less complex regimens are urgently required. METHODS: We compared the efficacy of an all oral DR tuberculosis drug regimen consisting of bedaquiline (25 mg/kg), delamanid (2.5 mg/kg), and linezolid (100 mg/kg) (BDL) on the mycobacterial load in the lungs and spleen of tuberculosis-infected mice during a treatment period of 24 weeks. This treatment was compared with the standard regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). Relapse was assessed 12 weeks after treatment. Two logistic regression models were developed to compare the efficacy of both regimens. RESULTS: Culture negativity in the lungs was achieved at 8 and 20 weeks of treatment with BDL and HRZE, respectively. After 14 weeks of treatment only 1 mouse had relapse in the BDL group, while in the HRZE group relapse was still observed at 24 weeks of treatment. Predictions from the final mathematical models showed that a 95% cure rate was reached after 20.5 and 28.5 weeks of treatment with BDL and HRZE, respectively. CONCLUSION: The BDL regimen was observed to be more effective than HRZE and could be a valuable option for the treatment of DR tuberculosis.
引用
- Pieterman ED, Keutzer L, van der Meijden A, et al. Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model. J Infect Dis. 2021. PMID: 33502537. doi:10.1093/infdis/jiab043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。